JKJakub Kaminski

Jakub Kaminski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakub Kaminski has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Research in the Field of Drug Design and Development

    by Grazyna Biala, Ewa Kedzierska, Marta Kruk-Slomka, Jolanta Orzelska-Gorka, Sara Hmaidan, Aleksandra Skrok, Jakub Kaminski, Eva Havrankova, Dominika Nadaska, Ivan Malik

    The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5–10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society’s insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrád group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.


  • Open Access

    The use of cannabinoid compounds in therapy in children - future or threat?

    by Joanna Cieszkowska, Julia Czerwik, Marta Czubala, Joanna Dmochowska, Jakub Kamiński

    Introduction and objective: Therapy with the use of "medical marijuana" is becoming more and more popular with patients, who often perceive it as a more natural and safe form of treatment. It is also more and more boldly considered by physicians in the pediatric population, especially when standard methods of pharmacotherapy prove insufficient. The following review focuses on the possibilities of using cannabis preparations in children with drug-resistant epilepsy, autism spectrum disorders and spasticity. It also draws attention to the possible side effects and risks of unjustified use of medical marijuana. State of knowledge: In the pediatric population, high efficacy and a favorable safety profile have been proven so far in the treatment of epileptic seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, and for the treatment of epileptic seizures in tuberous sclerosis complex, (TSC) . Although the therapy has been approved only for the above-mentioned indications, high hopes are also placed on the use of cannabinoids to treat the symptoms of other diseases and disorders, including spasticity and autism spectrum disorders. Conclusions: The research carried out so far gives hope for the possibility of using medical marijuana in other indications as well, as its use correlates with the reduction of i.a. symptoms of spasticity or autism spectrum disorders. At the same time, further studies are needed to assess the balance of benefits and potential risks of the therapy. Since recreational cannabis use in youth is known to be associated with serious adverse events, and medical cannabis use has a relatively strong placebo effect, decisions about its use should always be made carefully and based on scientific evidence.